OncoLink Cancer Treatment and Resources

Tuesday, December 11 - Scientific Presentations

ASH 2001

Combination Therapy with Thalidomide Plus Dexamethasone (THAL/DEX) for Newly Diagnosed Myeloma (MM)
Presenter: S. Vincent Rajkumar Presenter's Affiliation: Mayo Clinic, Rochester, MN Type of Session: Scientific Background VAD is standard induction chemotherapy for MM patients prior to undergoing stem cell transplant as part of aggressive therapy...
Fludarabine Compared with CVP Chemotherapy in Newly diagnosed Patients with Stages III and IV Low Grade Malignant Non-Hodgkin?s Lymphoma. Final Analysis of a Prospective Randomized Phase III Intergroup Study in 381 Patients
Presenter: A. Hagenbeek Presenter's Affiliation: Type of Session: Scientific Background In 1993, the EORTC lymphoma group initiated a prospective randomized trial in newly diagnosed, low grade non-Hodgkin?s lymphoma (NHL) patients to...
High incidence of Thalidomide-Associated Deep Vein Thrombosis (DVT) and Pulmonary Emboli (PE) when Chemotherapy is also administered
Presenter: Alan Liehten Presenter's Affiliation: University of Chicago Type of Session: Scientific Background Thalidomide is a sedative/anti-emetic that was given to women from 1956-1962. Some 12,000 birth defects have been attributed to the use...
Neurocognitive Assessment and detection of Stroke in Patients Diagnosed with Sickle Cell Disease: Neuropsychological Functioning and Magnetic Resonance Imaging (MRI)
Presenter: E. Vichinsky Presenter's Affiliation: Children's Hospital, Oakland, California Type of Session: Scientific Background Children who have sickle cell disease(SCD) are at risk for the development stroke or silent infarct, often resulting...
Persistence of Myeloma Protein for More than 1 year after Radiotherapy is an Adverse Prognostic Factor in Solitary Plasmacytoma of Bone
Presenter: Richard B. Wilder Presenter's Affiliation: M.D. Anderson Cancer Center Type of Session: Scientific Background Solitary plasmacytoma of bone (SPB) occurs infrequently, therefore no clear prognostic factors for this ailment, when treated...
Single Dose Pegfilgrastin (SD/01) Is as Effective as Daily Filgrastim Following ESHAP Chemotherapy for Subjects wtih Non-Hodgkin's Lymphoma or Hodgkin's Disease: Results of a Randomized, Open-Label Study
Presenter: Julie M. Vose Presenter's Affiliation: University of Nebraska Medical Center, Omaha, NE Type of Session: Scientific Background Pegfilgrastim is a pegylated form of filgrastim that has previously been shown to safely and effictively...
OncoLink I wish u knew...

Dr. Rebbeck talks about the role of cancer biology and genetics in cancer research and applying that to clinical care. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS